Suppr超能文献

皮质类固醇的使用时机影响住院 COVID-19 患者的死亡率。

Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients.

机构信息

Department of Emergency Medicine, Beaumont Hospital, Royal Oak, MI, USA.

Beaumont Health Research Institute, Royal Oak, MI, USA.

出版信息

Intern Emerg Med. 2021 Sep;16(6):1593-1603. doi: 10.1007/s11739-021-02655-6. Epub 2021 Feb 5.

Abstract

The optimal timing of initiating corticosteroid treatment in hospitalized patients is unknown. We aimed to assess the relationship between timing of initial corticosteroid treatment and in-hospital mortality in COVID-19 patients. In this observational study through medical record analysis, we quantified the mortality benefit of corticosteroids in two equally matched groups of hospitalized COVID-19 patients. We subsequently evaluated the timing of initiating corticosteroids and its effect on mortality in all patients receiving corticosteroids. Demographic, clinical, and laboratory variables were collected and employed for multivariable regression analyses. 1461 hospitalized patients with confirmed COVID-19 were analyzed. Of these, 760 were also matched into two equal groups based on having received corticosteroid therapy. Patients receiving corticosteroids had a lower risk of death than those who did not (HR 0.67, 95% CI 0.67-0.90; p = 0.01). Timing of corticosteroids was assessed for all 615 patients receiving corticosteroids during admission. Patients receiving first dose of corticosteroids > 72 h into hospitalization had a lower risk of death compared to patients with first dose at earlier time intervals (HR 0.56, 95% CI 0.38-0.82; p = 0.003). There was a mortality benefit in patients with > 7 days of symptom onset to initiation of corticosteroids (HR 0.56, 95% CI 0.33-0.95; p = 0.03). In patients receiving oxygen therapy, corticosteroids reduced risk of death in mechanically ventilated patients (HR 0.38, 95% CI 0.24-0.60; p < 0.001) but not in patients on high-flow or other oxygen therapy (HR 0.46, 95% CI 0.20-1.07; p = 0.07) and (HR 0.84, 95% CI 0.35-2.00; p = 0.69), respectively. Timing of corticosteroids initiation was related to in-hospital mortality for COVID-19 patients. Time from symptom onset > 7 days should trigger initiation of corticosteroids. In the absence of invasive mechanical ventilation, corticosteroids should be initiated if the patient remains hospitalized at 72 h. Hypoxia requiring supplemental oxygen therapy should not be a trigger for initiation of corticosteroids unless the timing is appropriate.

摘要

在住院患者中启动皮质类固醇治疗的最佳时机尚不清楚。我们旨在评估 COVID-19 患者初始皮质类固醇治疗时机与住院死亡率之间的关系。在这项通过病历分析的观察性研究中,我们在两组同样匹配的住院 COVID-19 患者中量化了皮质类固醇的死亡率获益。随后,我们评估了所有接受皮质类固醇治疗的患者中皮质类固醇的起始时间及其对死亡率的影响。收集了人口统计学、临床和实验室变量,并用于多变量回归分析。分析了 1461 例确诊 COVID-19 的住院患者。其中,760 例也根据接受皮质类固醇治疗分为两组。接受皮质类固醇治疗的患者死亡风险低于未接受皮质类固醇治疗的患者(HR 0.67,95%CI 0.67-0.90;p=0.01)。对所有 615 例住院期间接受皮质类固醇治疗的患者进行了皮质类固醇起始时间评估。与起始时间较早的患者相比,住院 72 小时后接受皮质类固醇治疗的患者死亡风险较低(HR 0.56,95%CI 0.38-0.82;p=0.003)。对于症状发作超过 7 天的患者,起始皮质类固醇治疗有获益(HR 0.56,95%CI 0.33-0.95;p=0.03)。在接受氧疗的患者中,皮质类固醇降低了机械通气患者的死亡风险(HR 0.38,95%CI 0.24-0.60;p<0.001),但对接受高流量或其他氧疗的患者没有影响(HR 0.46,95%CI 0.20-1.07;p=0.07),以及(HR 0.84,95%CI 0.35-2.00;p=0.69)。皮质类固醇起始时间与 COVID-19 患者的住院死亡率相关。症状发作超过 7 天后应启动皮质类固醇治疗。如果患者在 72 小时后仍住院,且无有创机械通气,则应开始皮质类固醇治疗。需要补充氧气治疗的缺氧不应作为启动皮质类固醇的触发因素,除非时机合适。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c8f/7864133/358c557c30bd/11739_2021_2655_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验